RESEARCH ARTICLE

Proteomic changes in a childhood acute lymphoblastic leukemia cell line during the adaptation to vincristine

Ana Laura Guzmán-Ortiz a,b, Gerardo Aparicio-Ozares b, Ricardo Valle-Rios a,c, Oscar Medina-Contreras a, Genaro Patiño-López a, Héctor Quezada a,∗

a Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
b Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico
c División de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico

Received 11 February 2017; accepted 28 March 2017
Available online 23 May 2017

KEYWORDS
Leukemia; Chemoresistance; Vincristine

Abstract

Introduction: Relapse occurs in approximately 20% of Mexican patients with childhood acute lymphoblastic leukemia (ALL). In this group, chemoresistance may be one of the biggest challenges. An overview of complex cellular processes like drug tolerance can be achieved with proteomic studies.

Methods: The B-lineage pediatric ALL cell line CCRF-SB was gradually exposed to the chemotherapeutic vincristine until proliferation was observed at 6 nM, control cells were cultured in the absence of vincristine. The proteome from each group was analyzed by nanoHPLC coupled to an ESI-ion trap mass spectrometer. The identified proteins were grouped into over-represented functional categories with the PANTHER classification system.

Results: We found 135 proteins exclusively expressed in the presence of vincristine. The most represented functional categories were: Toll receptor signaling pathway, Ras Pathway, B and T cell activation, CCKR signaling map, cytokine-mediated signaling pathway, and oxidative phosphorylation.

Conclusions: Our study indicates that signal transduction and mitochondrial ATP production are essential during adaptation of leukemic cells to vincristine, these processes represent potential therapeutic targets.

© 2017 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

∗ Corresponding author.
E-mail address: hquezada@himfg.edu.mx (H. Quezada).

http://dx.doi.org/10.1016/j.bmhimx.2017.03.005
1665-1146/© 2017 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Childhood acute lymphoblastic leukemia (ALL) is the most common type of cancer and the second leading cause of mortality among Mexican children. Overall cure rates of newly diagnosed ALL patients is around 80%, while chemoresistance is one of the main challenges in the relapsed population. Although much progress has been achieved in the detailed characterization of the molecular processes directly involved in drug tolerance of cancer cells, more research is needed to develop effective therapeutic strategies to resensitize chemoresistant cells.

Vincristine is a vinca alkaloid, which interacts with tubulin disrupting microtubule polymerization and favoring the cell cycle arrest in the M phase which is followed by induction of apoptosis. It is used in several stages of the ALL treatment. It has been reported that the P-glycoprotein MDRI actively pumps vincristine outside the cell reducing its therapeutic effect. Inactivation of intracellular vincristine by the myeloperoxidase has also been reported to contribute to resistance in some types of leukemia. Moreover, resistant leukemia, and other types of cancer cells, commonly show deregulated apoptosis and signaling pathways involved in survival. The complex state of resistance is the result of the concerted action of multiple interacting genes, proteins, and metabolites; and this scenario is well suited for characterization with the omic technologies. Proteomics studies provide an overview of the changes in the relative abundance of the proteins of a cell or tissue under different conditions. The characterization of proteins, as the final executors of cellular activities, may lead to identification of putative therapeutic targets and a better understanding of the pathological states. In the present work, we describe the changes in the proteome of a B-ALL cell line after adaptation to vincristine. Our results allowed the identification of targetable signaling and metabolic steps which may represent potential targets to resensitize leukemic cells to vincristine.

2. Methods

2.1. Growth conditions

The B-lineage pediatric ALL cell line CCRF-SB (ATCC CCL-120) was grown in RPMI-1640 with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 1% sodium pyruvate at 37°C under an atmosphere with 5% CO2.

2.2. Vincristine exposition

Cell viability was estimated with the MTT assay in 96 well plates. To determine the IC50, vincristine was added to 7 x10⁴ cells in 100 μL of media per well at 0, 1, 2, 3, 4, 5, 6, 8, 10, 20 and 40 nM in triplicate for 48 hours (Figure 1A). Gradual exposition was made as follows: 3 x10⁴ cells were cultured in 5 ml of media in the presence of 1 nM vincristine for five days, and then were exposed to 2 nM for the next five days, 3.5 nM for five days, 4.5 nM for three days, and 6 nM for four days (Figure 1B). In every step viable cells were enriched by centrifugation at 800 rpm 5 min, only the pelleted cells were transferred to the subsequent drug concentration. After 22 days of gradual exposition, cells proliferated in the presence of 6 nM vincristine, and cell viability was higher than 70%. Control cells were subjected to the same manipulations but cultured in the absence of vincristine.
Proteomic changes during adaptation to vincristine

2.3. Proteomic methods

Cells were washed with cold PBS and resuspended in 500 μL lysis buffer (4% SDS, 100 mM DTT, 100 mM TRIS pH 8.6 and a protease/phosphatase inhibitor cocktail, Thermo Scientific). Complete cell disruption was achieved by 20 cycles of 2 seconds sonication at 50% amplitude in a sonics 130-Watt Ultrasonic Processor and 5 seconds ice. After reduction (30 min at 40 °C) and alkylation (200 mM iodoacetamide, 30 min at room temperature in the darkness), 50 μg of protein were precipitated overnight with nine volumes of ethanol at -20 °C and washed twice with 90% ethanol. The dried pellet was dissolved in 50 mM guanidinium chloride, 20 mM TRIS and digested with mass spectrometry grade trypsin (1:50, Promega) overnight at 37 °C. The resulting peptides were desalted (sep-pak C18, cartridges, Waters), dried and kept at -80 °C until used.

Just before injection, peptides were dissolved in 50 μL of 0.1% formic acid. 5 μL of each sample were injected in triplicate to an Ultimate 3000 nanoHPLC system with a 1 cm Acclaim PepMap100 C18 pre-column and a 50 cm Acclaim PepMap100 C18 column. Peptides were eluted with a non-linear gradient from 5% to 90% acetonitrile with 0.1% formic acid in 240 min. The HPLC system was coupled to the ESI-Ion Trap mass spectrometer Amazon speed (Bruker Daltonics) operated in positive mode, 400-1400 m/z, the 20 most abundant ions were fragmented every 50 msec, single charged ions were excluded. The ion list was constructed with the Data Analysis software (Bruker Daltonics) and used for subsequent protein identification with the Mascot search engine using the SwissProt human database, two missed trypsin cleavages, carbamidomethylation as fixed modification, methionine oxidation as variable modification, and a peptide mass tolerance of 0.6 Da. Only those proteins identified in the three replicates were considered as valid identifications. Venn diagrams were drawn with the website from the University of Southern Mississippi (http://genevann.sourceforge.net/) and functional categories were analyzed with the statistical overrepresentation test of the PANTHER classification system5 (http://pantherdb.org) in which the analyzed list contained those proteins detected exclusively in the presence of vincristine whereas the reference list contained the proteins detected in both groups (with and without vincristine), the Bonferroni correction for multiple testing was not used. Only the functional categories with a fold enrichment value equal or higher than three were considered for further analysis.

3. Results

3.1. After gradual adaptation, the CCRF-SB cell line grew in the presence of 6 nM vincristine

Sudden vincristine exposition for 48 h resulted in IC50 of 10 nM (Figure 1A), which is similar to previous reports using other types of sensitive cell lines.5,16,17 However, gradual exposition allowed growth and cell duplication at 6 nM. The adaptation procedure depicted in Figure 1B resulted to be highly reproducible and allowed that cell density doubled during the last four days (from about 6x10^3 to 1.5 x10^6 cells/ml) keeping cell viability above 70%. These adapted cells were used for proteomic studies.

3.2. Approximately 15% of the proteome is differentially expressed after adaptation to vincristine

The proteomic approach used resulted in 849 and 858 valid identifications in the control and adapted cells respectively (Figure 2). As expected, most of the proteins (approximately 85%) were present in both conditions. However, 126 proteins were detected exclusively in the absence of vincristine and 135 in the presence of this drug. This result indicated that during the adaptation process, significant changes in the proteome took place.

To identify the cellular processes that mainly contributed to drug tolerance, the statistical overrepresentation test was made using the PANTHER classification system5. The 135 proteins identified exclusively in the presence of vincristine were compared with the 723 proteins common to both groups (Figure 2). This resulted in the identification of 17 overrepresented pathways and functions (Figure 3).
### Table 1 Details of the proteins assigned to the overrepresented pathways in adapted cells.

<table>
<thead>
<tr>
<th>Protein code</th>
<th>Protein name</th>
<th>Uniprot code</th>
<th>Protein class</th>
<th>Pathways</th>
<th>Protein function</th>
</tr>
</thead>
<tbody>
<tr>
<td>MP2K1</td>
<td>Dual specificity mitogen-activated protein kinase 1</td>
<td>Q02750</td>
<td>Kinase</td>
<td>Toll receptor signaling pathway, Ras pathway, B-cell activation, CCKR signaling map, T-cell activation</td>
<td>Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway</td>
</tr>
<tr>
<td>MK14</td>
<td>Mitogen-activated protein kinase 14</td>
<td>Q16539</td>
<td>Non-receptor serine/threonine protein kinase</td>
<td>Toll receptor signaling pathway, p53 pathway feedback loops 2, p38 MAPK pathway, Ras pathway, B-cell activation, CCKR signaling map</td>
<td>Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C</td>
</tr>
<tr>
<td>RB1</td>
<td>Retinoblastoma-associated protein</td>
<td>P06400</td>
<td>Transcription factor</td>
<td>p53 pathway feedback loops</td>
<td>Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C</td>
</tr>
<tr>
<td>RAC1</td>
<td>Ras-related C3 botulinum toxin substrate 1</td>
<td>P63000</td>
<td>Small GTPase</td>
<td>p38 MAPK pathway, Ras pathway, B-cell activation, CCKR signaling map, T-cell activation</td>
<td>Plasma membrane-associated small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state it binds to a variety of effector proteins to regulate cellular responses such as secretory processes, phagocytosis of apoptotic cells, epithelial cell polarization and growth-factor induced formation of membrane ruffles</td>
</tr>
<tr>
<td>VAV</td>
<td>Proto-oncogene vav</td>
<td>P15498</td>
<td>Guanyl-nucleotide exchange factor, signaling molecule</td>
<td>B-cell activation, T-cell activation</td>
<td>It couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation</td>
</tr>
<tr>
<td>CASP3</td>
<td>Caspase-3</td>
<td>P42574</td>
<td>Cysteine protease, protease inhibitor</td>
<td>CCKR signaling map, cell differentiation</td>
<td>Involved in the activation cascade of caspases responsible for apoptosis</td>
</tr>
<tr>
<td>Protein code</td>
<td>Protein name</td>
<td>Uniprot code</td>
<td>Protein class</td>
<td>Pathways</td>
<td>Protein function</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------</td>
<td>--------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ZAP70</td>
<td>Tyrosine-protein kinase ZAP-70</td>
<td>P43403</td>
<td>Non-receptor tyrosine protein kinase</td>
<td>T-cell activation, cell differentiation</td>
<td>Tyrosine kinase that plays an essential role in regulation of the adaptive immune response, regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. It also contributes to the development and activation of primary B-lymphocytes.</td>
</tr>
<tr>
<td>VRK1</td>
<td>Serine/threonine-protein kinase VRK1</td>
<td>Q99986</td>
<td>Non-receptor serine/threonine protein kinase</td>
<td></td>
<td>Serine/threonine kinase involved in Golgi disassembly during the cell cycle, following phosphorylation by PLK3 during mitosis, required to induce Golgi fragmentation.</td>
</tr>
<tr>
<td>IMA4</td>
<td>Importin subunit alpha-4</td>
<td>O00505</td>
<td>Transfer/carry protein</td>
<td>Cytokine-mediated signaling pathway, cell surface receptor signaling pathway</td>
<td>Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1.</td>
</tr>
<tr>
<td>IMA3</td>
<td>Importin subunit alpha-3</td>
<td>O00629</td>
<td>Transfer/carry protein</td>
<td>Cytokine-mediated signaling pathway, cell surface receptor signaling pathway</td>
<td>Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1.</td>
</tr>
<tr>
<td>RAP1A</td>
<td>Ras-related protein Rap-1A</td>
<td>P62834</td>
<td>Small GTPase</td>
<td>Cell surface receptor signaling pathway</td>
<td>Induces morphological reversion of a cell line transformed by a Ras oncogene, counteracts the mitogenic function of Ras, at least partly because it can interact with Ras GAPs and RAF in a competitive manner.</td>
</tr>
<tr>
<td>PIP5L</td>
<td>Putative PIP5K1A and PSMD4-like protein</td>
<td>A2A3N6</td>
<td>Kinase</td>
<td>Cell surface receptor signaling pathway, phospholipid metabolic process</td>
<td>Negligible PIP5 kinase activity. Binds to ubiquitinated proteins.</td>
</tr>
<tr>
<td>STK25</td>
<td>Serine/threonine-protein kinase 25</td>
<td>O00506</td>
<td>Kinase</td>
<td>Response to environmental stress, cell differentiation</td>
<td>Oxidant stress-activated serine/threonine kinase that may play a role in the response to environmental stress. Targets to the Golgi apparatus where it appears to regulate protein transport events, cell adhesion, and polarity complexes important for cell migration.</td>
</tr>
<tr>
<td>Protein code</td>
<td>Protein name</td>
<td>Uniprot code</td>
<td>Protein class</td>
<td>Pathways</td>
<td>Protein function</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------------</td>
<td>----------</td>
<td>------------------</td>
</tr>
<tr>
<td><strong>Modulators of signaling proteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZYX</td>
<td>Zyxin</td>
<td>Q15942</td>
<td>Cell junction protein, kinase modulator</td>
<td>Nervous system development</td>
<td>Adhesion plaque protein. Binds alpha-actinin and the CRP protein. Important for targeting TES and ENA/VASP family members to focal adhesions and for the formation of actin-rich structures. It may be a component of a signal transduction pathway that mediates adhesion-stimulated changes in gene expression. A cell-adhesion and mechanotransducer protein.</td>
</tr>
<tr>
<td>AT2A2</td>
<td>Sarcoplasmic/endoplasmic reticulum calcium ATPase 2</td>
<td>P16615</td>
<td>Cation transporter, ion channel</td>
<td>Homeostatic process</td>
<td>This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen.</td>
</tr>
<tr>
<td>CK5P3</td>
<td>CDK5 regulatory subunit-associated protein 3</td>
<td>Q96JB5</td>
<td>Probable tumor suppressor</td>
<td>Regulation of catalytic activity</td>
<td>Probable tumor suppressor initially identified as a CDK5R1 interactor controlling cell proliferation. Negatively regulates NF-kappa-B-mediated gene transcription through the control of RELA phosphorylation. Also, it regulates mitotic G2/M transition checkpoint and mitotic G2 DNA damage checkpoint.</td>
</tr>
<tr>
<td>OXSR1</td>
<td>Serine/threonine-protein kinase OSR1</td>
<td>O95747</td>
<td>Kinase</td>
<td>Regulation of catalytic activity</td>
<td>Regulates downstream kinases in response to environmental stress. It may also have a function in regulating the actin cytoskeleton.</td>
</tr>
<tr>
<td><strong>Production of mitochondrial ATP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATPK</td>
<td>ATP synthase subunit f, mitochondrial</td>
<td>P56134</td>
<td>ATP synthase</td>
<td>Oxidative phosphorylation</td>
<td>Mitochondrial membrane ATP synthase (F1F0 ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane, which is generated by electron transport complexes of the respiratory chain.</td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Protein code</th>
<th>Protein name</th>
<th>Uniprot code</th>
<th>Protein class</th>
<th>Pathways</th>
<th>Protein function</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDUS8</td>
<td>NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial</td>
<td>O00217</td>
<td>Dehydrogenase, reductase</td>
<td>Oxidative phosphorylation</td>
<td>Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain.</td>
</tr>
<tr>
<td>SDHB</td>
<td>Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial</td>
<td>P21912</td>
<td>Dehydrogenase</td>
<td>Oxidative phosphorylation</td>
<td>Iron-sulfur protein (IP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).</td>
</tr>
<tr>
<td>QCR1</td>
<td>Cytochrome b-c1 complex subunit 1, mitochondrial</td>
<td>P31930</td>
<td>Metalloprotease</td>
<td>Oxidative phosphorylation</td>
<td>This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the mitochondrial respiratory chain. This protein may mediate formation of the complex between cytochromes c and c1.</td>
</tr>
<tr>
<td>COX41</td>
<td>Cytochrome c oxidase subunit four isoform 1, mitochondrial</td>
<td>P13073</td>
<td>Oxidase</td>
<td>Oxidative phosphorylation</td>
<td>This protein is one of the nuclear-coded polypeptide chains of cytochrome c oxidase, the terminal oxidase in mitochondrial electron transport.</td>
</tr>
<tr>
<td>ETFA</td>
<td>Electron transfer flavoprotein subunit alpha, mitochondrial</td>
<td>P13804</td>
<td>Dehydrogenase</td>
<td>Homeostatic process</td>
<td>The electron transfer flavoprotein serves as a specific electron acceptor for several dehydrogenases, including five acyl-CoA dehydrogenases, glutaryl-CoA, and sarcosine dehydrogenase. It transfers the electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase).</td>
</tr>
</tbody>
</table>
Table 1  (Continued)

<table>
<thead>
<tr>
<th>Protein code</th>
<th>Protein name</th>
<th>Uniprot code</th>
<th>Protein class</th>
<th>Pathways</th>
<th>Protein function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytoskeletal dynamics</td>
<td>MAP4</td>
<td>Microtubule-associated protein 4</td>
<td>P27816</td>
<td>-</td>
<td>Cell differentiation</td>
</tr>
<tr>
<td>Others</td>
<td>APOA1</td>
<td>Apolipoprotein A-I</td>
<td>P02647</td>
<td>-</td>
<td>Phospholipid metabolic process, steroid metabolic process, cell differentiation</td>
</tr>
<tr>
<td></td>
<td>DCXR</td>
<td>L-xylulose reductase</td>
<td>Q7Z4W1</td>
<td>Dehydrogenase, reductase</td>
<td>Steroid metabolic process</td>
</tr>
<tr>
<td></td>
<td>SPRE</td>
<td>Sepiapterin reductase</td>
<td>P35270</td>
<td>Dehydrogenase, reductase</td>
<td>Steroid metabolic process</td>
</tr>
<tr>
<td></td>
<td>RAD50</td>
<td>DNA repair protein RAD50</td>
<td>Q92878</td>
<td>Oxidase, transferase</td>
<td>Homeostatic process</td>
</tr>
<tr>
<td></td>
<td>TFR1</td>
<td>Transferrin receptor protein 1</td>
<td>P02786</td>
<td>Receptor</td>
<td>Ion transport</td>
</tr>
</tbody>
</table>
Proteomic transduction, tolerance

Interestingly, processes without vincristine. This study addressed the question of which are the cellular processes that sensitive leukemic cells induced to achieve tolerance to vincristine. To this end, the B-ALL cell line CCRF-SB was gradually exposed until cell proliferation was gradual. By contrast, acquired chemoresistance is developed after

to which 30 different proteins were assigned (Table 1). Interestingly, 43% of the proteins in Table 1 and 53% of the pathways in Figure 3 were directly involved in signal transduction, whereas 13% of the proteins were involved in regulation of signaling and 20% in oxidative phosphorylation.

4. Discussion

This study addressed the question of which are the cellular processes that sensitive leukemic cells induced to achieve tolerance to vincristine. To this end, the B-ALL cell line CCRF-SB was gradually exposed until cell proliferation was gradual. By contrast, acquired chemoresistance is developed after

Table 1 (Continued)

<table>
<thead>
<tr>
<th>Protein code</th>
<th>Protein name</th>
<th>Uniprot code</th>
<th>Protein class</th>
<th>Pathways</th>
<th>Protein function</th>
</tr>
</thead>
<tbody>
<tr>
<td>THTM</td>
<td>3-mercaptopropionate sulfur transferase</td>
<td>P25325</td>
<td>Transfer/carrier protein, transferase</td>
<td>Ion transport</td>
<td>Transfer of a sulfur ion to cyanide or other thiol compounds. In combination with cysteine aminotransferase (CAT), contributes to the catabolism of cysteine and is an important producer of hydrogen sulfide in the brain, retina and vascular endothelial cells. Hydrogen sulfide H2S is an important synaptic modulator, signaling molecule, smooth muscle contractor and neuroprotectant. Its production by the 3MST/CAT pathway is regulated by calcium ions.</td>
</tr>
</tbody>
</table>

Figure 2 Venn diagram of valid protein identifications with and without gradual exposition of the CCRF-SB cell line to 6 nM vincristine.

Figure 3 Functional categories overrepresented in adapted cells. The analysis was made with the statistical overrepresentation test of the PANTHER classification system as described in the Proteomic methods section.

observed in the presence of 6 nM vincristine, and the corresponding proteomic profile was compared to that of cells grown in the absence of the chemotherapeutic drug.

Chemoresistance may be intrinsic or acquired. The ability to tolerate high concentrations of chemotherapeutics of an intrinsically resistant cancer cell is not developed as a result of an exposition to the drugs; instead it is the result of genetic abnormalities the cell carries before exposition.

Continued...
the cancer cell is exposed to the drug and may be the result of molecular evolution of resistant clones.\textsuperscript{19} Experimental settings to study acquired chemoresistance include the comparison of matched paired samples at diagnosis and after relapse\textsuperscript{20} or the comparison of sensitive cell lines and resistant sublines which are obtained after prolonged exposure (several months) to the drug.\textsuperscript{21} It is likely that resistant clones may have evolved during the gradual adaptation protocol depicted in Figure 1B. However, the low growth rate, the short time of exposure (22 days) and the fact that it was highly reproducible when it was assayed from frozen stocks of sensitive cells suggest that the observed tolerance to vincristine was the result of induction of cellular processes to counteract the cytotoxic effect of the drug rather than the result of events involving mutation, selection, and evolution of resistant clones.

The cytotoxic effects of drugs are dependent on the concentration and the time of exposure. In many studies, cells have been exposed to relatively high concentrations for short times (24 or 48 h). In such experimental setting, at concentrations close to the IC50, cells are not growing actively but remain viable and quiescent. Our results showed that even at concentration as low as 1 nM for five days, a reduction in cell viability was observed (Figure 1B). The gradual adaptation protocol used allowed cell division even after four days of exposition to 6 nM. By contrast, in cells exposed to 6 nM vincristine for 48 h without previous adaptation, no cellular division was observed (data not shown). In this regard, our results may be complementary to previous studies and may reflect some aspects of leukemic cells in vivo during advanced stages of therapy.

Successful adaptation was also reflected in the absence of overrepresented categories typically associated with cell death (Figure 3).

Interestingly, 43\% of the proteins included in the overrepresented categories of adapted cells (namely MP2K1, MK14, RB1, RAC1, VAV, CASP3, ZAP70, VRK1, IMA4, IMA3, RAP1A, PI3P5L, and STK25) were involved in signaling pathways like Toll receptor signaling pathway, Ras pathway, B- and T-cell activation, CCKR signaling map, p53 pathway feedback loops, p38 MAPK pathway, cytokine-mediated signaling pathways, cell surface receptor signaling pathway (Table 1); some of them have been reported to be important for growth and proliferation of lymphocytes and chemoresistance.\textsuperscript{22-24} For example, the MP2K1, MK14 and RAC1 proteins positively regulate the Ras pathway, and the MP2K1 protein is an essential component of the MAP kinase pathway. These signal transduction pathways have been associated with tumorigenesis and chemoresistance.\textsuperscript{22,25,26} Inhibition of the MP2K1 protein with PD-0325901, Bay86-9766, trametinib, selumetinib, pimasertib or GDC-0973 has been studied in advanced clinical trials.\textsuperscript{22} The MK14 protein has been reported to be closely associated with drug resistance in leukemia,\textsuperscript{27} and the RAC1 protein has been proposed as a therapeutic target for gefitinib-resistant non-small-cell lung cancer and pancreatic cancer cells.\textsuperscript{28,29} and its overexpression has been associated with poor prognosis in non-small-cell lung cancer.\textsuperscript{30} Deregulation of the VAV protein has been reported in neuroblastoma, melanoma, pancreatic, lung and breast cancers, and B-cell chronic lymphocytic leukemia.\textsuperscript{31} Furthermore, the proteins ZYX, AT2A2, CK5P3 and OXSR1, which were assigned to categories like Nervous system development, Homeostatic process and Regulation of catalytic activity (Table 1), are modulators of signaling proteins.\textsuperscript{32,33} By contrast, in the control cells, any pathway resulted to be overrepresented when the statistical over-representation test was made comparing the 126 proteins detected exclusively in the absence of vincristine with the proteins detected in both groups (with and without vincristine). This difference may indicate that some signaling proteins and pathways may be crucial for adaptation to vincristine. In this regard, some drugs have been developed to target signaling pathways and to overcome drug tolerance.\textsuperscript{32,35} Further research is necessary to explore this possibility during the gradual adaptation to vincristine.

The cell-adhesion and mechanotransducer protein ZYX was assigned to the Nervous system development category (Table 1). However, it has been reported to participate in signal transduction pathways leading to cell migration, proliferation, and tumorigenesis.\textsuperscript{32} The ZYX protein is upregulated in human breast cancer and positively correlates with metastasis. It has been proposed as a potential therapeutic target in breast cancer and as an early detection biomarker in non-small cell lung cancer.\textsuperscript{31,35}

Verrills et al. reported the proteomic changes of the T-lineage ALL cell line CCRF-CEM after exposition to 2, 4 and 8 nM vincristine for 24 h using two-dimensional polyacrylamide electrophoresis and MALDI-TOF mass spectrometry.\textsuperscript{17} They found that vincristine-induced changes in the expression of 39 proteins and that a resistant subline differentially expressed 42 proteins mainly involved in cytoskeleton metabolism.\textsuperscript{17} Other differentially expressed proteins resulted to be regulators of apoptosis, chaperones, gene regulators and ribosomal proteins. The involvement of alterations in the metabolism of actin and tubulin during the cellular response to vincristine was confirmed in a subsequent study by the same group using primary cells engrafted into NOD/SCID mice and intraperitoneal vincristine (0.5 mg/kg every seven days).\textsuperscript{36} Results shown in Figure 3 and Table 1 were based in comparisons of those proteins identified exclusively in the adapted cells versus the shared proteins (Figure 2). As cytoskeletal metabolism is very active in every cell, many cytoskeletal regulating proteins were among the 723 shared proteins; this may have prevented the overrepresentation of cytoskeletal metabolism in the adapted cells. To detect changes in the relative abundance of the shared proteins, a quantitative analysis is required. However, the microtubule-associated protein 4 (MAP4) was assigned to the overrepresented pathway Cell differentiation (Table 1). This protein promotes microtubule assembly and may reflect a more active cytoskeletal metabolism in the adapted cells compared to the control cells. Further research is necessary to explore this possibility.

After the combined effect of signaling pathways, Oxidative phosphorylation had the second highest percentage of proteins among the overrepresented pathways (Table 1). This suggested that a higher ATP production is needed to deal with the presence of vincristine. In this regard, modulation of the metabolic peculiarities of cancer cells has been proposed as a promising therapeutic strategy.\textsuperscript{37,38} The inhibitors metformin, rotenone, α-tocopheryl succinate, benzylisothiocyanate, oligomycin and resveratrol have been used to target mitochondrial energetic metabolism.\textsuperscript{38} Our results
suggest that these compounds may be good candidates to overcome tolerance to vincristine.

Detection of the TFR1 and THTM proteins resulted in the overrepresentation of the ion transport category in the adapted cells (Table 1 and Figure 3). The protein TFR1 may have contributed to B-cell growth through iron uptake. Interestingly, this protein has been implicated in tamoxifen in a subgroup of ER+/luminal-like breast cancer. Calcium is translocated from the cytosol to the sarcoplasmic reticulum lumen by the ATZAZ protein (assigned to the Homeostatic process category in Table 1). Inhibition of this protein has been proposed as a promising strategy to overcome multidrug-resistance in leukemic cells. Moreover, calcium signaling modulates the activity of the THTM protein which participates in the production of hydrogen sulfide (Table 1). Interestingly, this compound has been reported to be involved in chemoresistance of lung adenocarcinoma cells, and inhibition of hydrogen sulfide-producing enzymes has been proposed as a strategy to sensitize resistant cells.

DNA repair protein RAD50 was assigned to the overrepresented category Homeostatic process (Table 1). As part of the MRN complex, this protein has been proposed as a predictor for poor prognosis and chemoresistance in gastric cancer.

Unexpectedly, p-glycoprotein was not detected in our proteomic analysis of adapted cells. This may be due to the low relative abundance of this protein compared to other cellular proteins. To achieve higher sensitivity, peptide mixture can be fractionated in a previous HPLC run before the nanoHPLC-ESI-MS analysis.

Although monoculture of cell lines is a useful model for in vitro studies, the influence of the bone marrow microenvironment in chemoresistance cannot be studied in this regard. C-culture of bone marrow stromal cells and leukemic cells will certainly give more information of the involved mechanisms.

As a general rule, findings from the omic analyses must be confirmed with traditional techniques like Western blot, flow cytometry, ELISA or RT-PCR. Confirmation would be necessary only for those few genes of interest in a particular study. Although we used stringent criteria for protein identification in the MASCOT search engine, only those proteins identified in the three analytical replicates were considered as valid identifications, and only pathways with a fold enrichment value higher than or equal to three were considered as overrepresented. Our results must be validated if they are to be used in further studies aimed to deepen into the molecular mechanisms involved in tolerance to vincristine.

Ethical responsibilities

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of their patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article

Funding

Federal funding HIM/2015/053 SSA1183, HIM/2016/026 SSA1222 for HQ and HIM/2014/003 SSA1129 for GPL. CONACYT grant 589666 for ALGO.

Conflict of interest

The authors declare no conflict of interest of any nature.

References


